atorvastatin has been researched along with Left Ventricular Hypertrophy in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Khairat, I; Khedr, NF; Werida, R | 1 |
| Liu, D; Nie, W; Shi, K; Xie, D; Yang, P; Yu, B; Zhang, H | 1 |
| Ata, Y; Aydın, U; Düzyol, Ç; Koçoğulları, CU; Orhan, AL; Türk, T; Yılmaz, M | 1 |
| Jia, CW; Jing, HM; Pan, M; Qin, XT; Shen, AG | 1 |
| Fukumoto, Y; Rashid, M; Seto, M; Shimokawa, H; Tawara, S; Yano, K | 1 |
| Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C | 1 |
| Geng, J; Kang, W; Wang, W; Zhang, Y; Zhao, Z; Zhiming, GE | 1 |
| Hu, SJ; Kang, L | 1 |
| Aubin, MC; Carrier, M; Forcillo, J; Maltais, S; Perrault, LP; Shi, YF; Tardif, JC | 1 |
| Aguilar, C; Rodríguez-Delfín, L; Ventura, F | 1 |
| Liebson, PR | 1 |
| Chen, SN; Halder, T; Marian, AJ; Nagueh, SF; Roberts, R; Senthil, V; Tsybouleva, N; Willerson, JT | 1 |
| Liu, Y; Sheng, L; Ye, P; Zhang, C | 1 |
| Chen, HJ; Chen, JZ; Chen, TG; Wang, LH; Yao, L; Yu, M | 1 |
| Bezerra, DG; Lacerda Andrade, LM; Mandarim-de-Lacerda, CA; Pinto da Cruz, FO | 1 |
| Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF | 1 |
6 trial(s) available for atorvastatin and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia.
Topics: Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Egypt; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Inflammation Mediators; Lipids; Male; Middle Aged; Prospective Studies; Rosuvastatin Calcium; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Efficiency of postoperative statin treatment for preventing new-onset postoperative atrial fibrillation in patients undergoing isolated coronary artery bypass grafting: A prospective randomized study.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Coronary Artery Bypass; Echocardiography; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Middle Aged; Postmenopause; Postoperative Complications; Prospective Studies; Treatment Outcome | 2015 |
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Leukocytes; Male; Pravastatin; Pyrroles; Quinolines; rac1 GTP-Binding Protein; ras Proteins; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2009 |
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2009 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling | 2008 |
10 other study(ies) available for atorvastatin and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Apoptosis; Atorvastatin; Cell Line; Cell Survival; Disease Models, Animal; Hypertrophy, Left Ventricular; Male; MicroRNAs; Myocytes, Cardiac; Nerve Tissue Proteins; Rats, Sprague-Dawley; Signal Transduction; Ventricular Function, Left; Ventricular Remodeling | 2018 |
[Effect of atorvastatin on ACE2 expression in pressure overload induced cardiac hypertrophy in rats].
Topics: Angiotensin-Converting Enzyme 2; Animals; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Ligation; Male; Peptidyl-Dipeptidase A; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2008 |
Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; MEF2 Transcription Factors; Myocardium; Protein Kinase C; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Time Factors; Transcription Factors; Ventricular Remodeling | 2010 |
[Effects of atorvastatin on p27 protein expression and cardiomyocytes apoptosis in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cyclin-Dependent Kinase Inhibitor p27; Heptanoic Acids; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; RNA, Messenger | 2008 |
Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy.
Topics: Angiotensin II; Animals; Aorta; Atorvastatin; Coronary Vessels; Cyclic GMP; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Echocardiography; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Nitrates; Nitrites; Pyrroles; Random Allocation; Swine; Vasodilation; Ventricular Dysfunction, Left | 2011 |
[Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy].
Topics: Animals; Atorvastatin; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Peptidyl-Dipeptidase A; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Atorvastatin; Cardiomyopathy, Hypertrophic; Cholesterol; Disease Models, Animal; DNA, Mitochondrial; Extracellular Signal-Regulated MAP Kinases; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Myosin Heavy Chains; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyrroles; Rabbits; Ventricular Function, Left | 2005 |
Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo.
Topics: Animals; Atorvastatin; Cells, Cultured; Down-Regulation; Heptanoic Acids; Hypertrophy, Left Ventricular; Male; PPAR gamma; Pyrroles; Rats; Rats, Sprague-Dawley | 2006 |
Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Blotting, Western; Connexin 43; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Immunohistochemistry; Lipid Metabolism; Lipids; Male; Microscopy, Electron, Transmission; Myocardium; Natriuretic Peptide, Brain; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2007 |
Atorvastatin attenuates cardiomyocyte loss in adult rats from protein-restricted dams.
Topics: Animals; Atorvastatin; Blood Pressure; Body Mass Index; Cardiomegaly; Diet, Protein-Restricted; Fibrosis; Heptanoic Acids; Hypertrophy, Left Ventricular; Male; Myocardial Reperfusion; Myocytes, Cardiac; Perfusion; Pyrroles; Rats; Rats, Wistar | 2008 |